OCALIVA received FDA accelerated approval in 2016 for the treatment of PBC in adults with an inadequate response to or intolerance of ursodeoxycholic acid (UDCA). Since then, OCALIVA has played a ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher ...

Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

A two-way relationship was observed between T1D and primary biliary cholangitis (PBC): genetically predicted T1D increased ...

The Business Research Company's Primary Biliary Cholangitis Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ...